<DOC>
	<DOCNO>NCT01798602</DOCNO>
	<brief_summary>The CHAT Pilot Trial design compare rosuvastatin placebo patient suspect H1N1 . The pilot study assess feasibility clinical protocol , study procedure .</brief_summary>
	<brief_title>Collaborative H1N1 Adjuvant Treatment ( CHAT ) Pilot Trial</brief_title>
	<detailed_description>This trial pilot study assess feasibility acceptability double blind randomize control trial ( RCT ) evaluate efficacy rosuvastatin adjuvant therapy H1N1 influenza</detailed_description>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Critically ill adult patient &gt; 16 year age admit adult ICU reason suspect , probable confirm novel swine origin influenza A/H1N1 infection Requiring mechanical ventilation ( invasive noninvasive ) Receiving antiviral therapy ( medication dose intended duration ) &lt; 72 hour Clinicians must 'moderate ' , 'high ' 'moderate high ' index suspicion H1N1 Age &lt; 16 year Do resuscitate reintubate order documented chart anticipate withdrawal life support Weight &lt; 40 kg Unable receive unlikely absorb enteral study drug ( e.g . incomplete complete bowel obstruction , intestinal ischemia , infarction , short bowel syndrome ) Rosuvastatin specific exclusion : 1 . Already receive statin ( Atorvastatin , Lovastatin , Simvastatin , Pravastatin , Rosuvastatin ) 2 . Allergy intolerance statins 3 . Receiving niacin , fenofibrate , cyclosporine , gemfibrozil , lopinavir , ritonavir plan use oral contraceptive estrogen therapy ICU stay 4 . CK exceed 10 time ULN ALT exceed 8 time ULN Severe chronic liver disease ( ChildPugh Score 1115 ) ( see Appendix 6 ) Previous enrolment trial Pregnancy breast feeding At time enrolment , patient must receive &gt; 72 hour antiviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>H1N1</keyword>
	<keyword>Rosuvastatin</keyword>
</DOC>